Advanced Malignancies
Showing NaN - NaN of 13
Advanced Malignancies, NSCLC, Ovarian Cancer Trial in Worldwide (Avelumab, Lorlatanib, Talazoparib)
Recruiting
- Advanced Malignancies
- +4 more
- Avelumab
- +7 more
-
Fayetteville, Arkansas
- +61 more
Jan 10, 2023
Advanced Malignancies, Metastatic Cancer Trial in Worldwide (INCAGN01876, Nivolumab, Ipilimumab)
Completed
- Advanced Malignancies
- Metastatic Cancer
- INCAGN01876
- +2 more
-
Los Angeles, California
- +37 more
Dec 6, 2022
Recurrent Cancer, Metastatic Cancer, Advanced Malignancies Trial (INCAGN01876, retifanlimab)
Recruiting
- Recurrent Cancer
- +3 more
- INCAGN01876
- retifanlimab
-
Birmingham, Alabama
- +17 more
Dec 13, 2022
Advanced Malignancies Trial in United States (Toripalimab, Recombinant Humanized anti-PD-1 Monoclonal Antibody)
Active, not recruiting
- Advanced Malignancies
- Toripalimab, Recombinant Humanized anti-PD-1 Monoclonal Antibody
-
Santa Monica, California
- +13 more
Dec 12, 2021
Solid Tumors, Advanced Malignancies, Metastatic Cancer Trial in Spain, United Kingdom, United States (Azacitidine,
Advanced Malignancies, Metastatic Cancer Trial in Worldwide (INCAGN01949)
Completed
- Advanced Malignancies
- Metastatic Cancer
-
New Brunswick, New Jersey
- +7 more
May 6, 2020
Advanced Cancer, Advanced Malignancies Trial in Australia, Spain, United States (Cemiplimab, Hypofractionated radiotherapy,
Completed
- Advanced Cancer
- Advanced Malignancies
- Cemiplimab
- +7 more
-
Gilbert, Arizona
- +46 more
Jan 23, 2020
Advanced Malignancies Trial in United States (MEDI0680 (AMP-514))
Completed
- Advanced Malignancies
- MEDI0680 (AMP-514)
-
New Haven, Connecticut
- +5 more
Oct 4, 2017